Indivior Pharmaceuticals Financial Ratios
NASDAQ: INDVHealth CareBiotechnology: Pharmaceutical PreparationsUSD
35.83+0.38 (+1.07%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Indivior Pharmaceuticals ratio analysis
Indivior Pharmaceuticals earned a net margin of 16.9% in FY 2025, up from 0.6% a year earlier. Gross margin was 80.2% compared with a median of 83.5% over the prior 4 years. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Indivior Pharmaceuticals financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| P/E ratio (at fiscal year end) | 21.79 | 249.80 | — | — | — |
| Price / sales | 3.60 | 1.39 | 1.91 | 3.36 | 3.18 |
| Price / book | — | — | — | — | 20.77 |
| Gross margin | 80.2% | 80.6% | 84.1% | 83.1% | 83.9% |
| Operating margin | 21.1% | 3.2% | -13.9% | -8.5% | 26.9% |
| Net margin | 16.9% | 0.6% | -11.5% | -4.7% | 25.9% |
| Free cash flow margin | -7.5% | 0.6% | -28.2% | -1.0% | 44.1% |
| Return on equity (ROE) | — | — | — | — | 169.4% |
| Return on assets (ROA) | 17.5% | 0.5% | -7.2% | -2.4% | 11.2% |
| Debt / equity | — | — | — | — | 2.00 |
| Current ratio | 0.71 | 0.90 | 0.98 | 1.24 | 1.80 |
| Revenue growth | 4.3% | 8.7% | 21.3% | 13.9% | — |
| EPS growth | 3,180.0% | — | — | — | — |